Enterprise Value
23.19M
Cash
429.5M
Avg Qtr Burn
-19.6M
Short % of Float
35.02%
Insider Ownership
0.33%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JEMPERLI (Dostarlimb-gxly) Details Solid tumor/s, Cancer, Endometrial cancer | Approved Quarterly sales | |
Dostarlimab Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Imsidolimab (ANB019) (anti-IL-36R) Details Ichthyosis, Acne, Hidradenitis suppurativa, EGFRi-mediated skin toxicity, Palmoplantar pustulosis, Generalized pustular psoriasis | Phase 3 Data readout | |
Dostarlimab Details Ovarian cancer | Phase 3 Data readout | |
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Rheumatoid arthritis, Autoimmune disease | Phase 2b Data readout | |
ANB032 (BTLA agonist) Details Atopic dermatitis | Phase 2b Data readout | |
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Ulcerative colitis | Phase 2 Initiation | |
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Alopecia areata, Vitiligo, Skin disease/disorder | Failed Discontinued | |
Etokimab (ANB020) Anti-IL-33 Details Chronic Rhinosinusitis with Nasal Polyps | Failed Discontinued |